SynergyFinder: Advanced Drug-Combination Analysis Now Available on Vecura

What is SynergyFinder?

SynergyFinder is a mature R/Bioconductor statistical analysis package designed for pre-clinical drug-combination research. It quantifies synergy and sensitivity metrics from experimental dose-response matrix data using four classical reference models: HSA, Bliss, Loewe, and ZIP.

It helps users rigorously analyze viability or inhibition data to determine if drug combinations exhibit synergistic, additive, or antagonistic effects. It is especially useful for researchers who need to interpret experimental drug-screen data to prioritize effective combinations for further development.

What can users do with SynergyFinder on Vecura?

With SynergyFinder on Vecura, users can:

• Quantify Drug Interactions: Apply popular models like ZIP (Zero Interaction Potency) to score synergy and antagonism across dose-response grids.
• Characterize Sensitivity: Calculate crucial metrics such as Relative IC50, Relative Inhibition (RI), and the Combination Sensitivity Score (CSS) based on 4-parameter log-logistic fits.
• Visualize Surfaces: Generate 2D heatmaps and 3D interaction surfaces to pinpoint specific concentration windows where synergy is strongest.
• Analyze Statistical Significance: Utilize bootstrap resampling for blocks with technical replicates to obtain confidence intervals and p-values, ensuring the robustness of the identified interactions.

What the output means

The output provides comprehensive summary tables and granular surface datasets that detail the synergy scores per-block and per-concentration-pair, alongside robust sensitivity metrics.

This output should be used to support scientific decision-making. It does not replace experimental validation.

Why this matters

In pre-clinical drug discovery, identifying effective drug combinations is critical for overcoming resistance and improving therapeutic efficacy. However, translating raw viability data into actionable insights requires complex statistical modeling that can be prone to noise and technical variability.

By providing standardized, automated implementations of established reference models, SynergyFinder helps researchers move beyond subjective interpretation. It ensures that the identification of synergistic drug interactions is based on rigorous statistical grounds, enabling more reliable prioritization of candidates for subsequent validation.

• Developed by: The Institute for Molecular Medicine Finland (FIMM), University of Helsinki
• Source: Official GitHub Repository
• Reference: SynergyFinder Plus Paper (Genomics Proteomics Bioinformatics 2022)